---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-254658"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2026-06-03T12:30:20+00:00"
generated_at: "2026-06-03T12:36:07.432476+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Cardiff Oncology furnishes investor presentation with Phase 2 CRDF-004 interim results

## Summary
- Presentation covers interim data from randomized Phase 2 CRDF-004 trial of onvansertib + SoC in first-line RAS-mutated mCRC.
- Presentation also details registrational study plans for onvansertib in this indication.
- No specific efficacy or safety endpoints were disclosed in the filing itself; details are in furnished Exhibit 99.1.

## SEC filing metadata
- accession: 0001193125-26-254658
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2026-06-03T12:30:20+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000119312526254658/0001193125-26-254658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000119312526254658/crdf-20260603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-254658
- JSON: https://secwatch.observer/filing/0001193125-26-254658.json
- Plain text: https://secwatch.observer/filing/0001193125-26-254658.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.